Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women

被引:248
作者
Lindsay, R
Gallagher, JC
Kleerekoper, M
Pickar, JH
机构
[1] Helen Hayes Hosp, Dept Internal Med, W Haverstraw, NY 10993 USA
[2] Creighton Univ, Sch Med, Bone Metab Unit, Omaha, NE USA
[3] Wayne State Univ, Sch Med, Div Endocrinol, Detroit, MI USA
[4] Wyeth Ayerst Res, Clin Res & Dev, Philadelphia, PA USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2002年 / 287卷 / 20期
关键词
D O I
10.1001/jama.287.20.2668
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Lower-than-commonly-prescribed doses of conjugated equine estrogens (CEEs) with medroxyprogesterone acetate (MPA) improve vasomotor symptoms and vaginal atrophy, provide acceptable bleeding and lipid profiles, and afford endometrial protection. This lower-dose therapy's protection against loss of bone mineral density (BMD) associated with menopause has not been thoroughly investigated. Objective To determine the effects of lower doses of CEEs only or CEEs-MPA on spine and hip BMD, total body bone mineral content (BMC), and biochemical markers of bone turnover in postmenopausal women. Design and Setting Two-year randomized, double-blind, placebo-control led sub-study of the Women's Health, Osteoporosis, Progestin, Estrogen trial, conducted at 19 US centers between August 1995 and October 2000. Participants Eight hundred twenty-two healthy postmenopausal women aged 40 to 65 years who were within 4 years of their last menstrual period. Interventions Patients were randomly assigned to receive CEEs, 0.625; CEEs, 0.625 and MPA, 2.5; CEEs, 0.45; CEEs, 0.45 and MPA, 2.5; CEEs, 0.45 and AAPA, 1.5; CEES, 0.3; CEEs 0.3 and MPA, 1.5 (all doses in mg/d); or placebo for 2 years. All participants also received elemental calcium at 600 mg/d. Main Outcome Measures Changes from baseline in spine and total hip BMD, total body BMC, and biochemical markers of bone turnover (serum osteocalcin and urinary cross-linked N-telopeptides of type I collagen), assessed at 6-month intervals and compared among treatment groups with a modified intention-to-treat approach. Results At 24 months, women assigned to all of the active treatment groups had significant gains from baseline (P<.001) in spine and hip BMD and total body BMC (except total body BMC in the group receiving CEEs, 0.3 mg/d). These changes were significantly different from those in the placebo group, in which losses of bone mass in spine and total body were evident over the course of the study (P<.001). The loss in hip BMD from baseline in the placebo group was significant at 18 (P=.02) but not at 24 months (P=.06). Osteocalcin and N-telopeptides of type I Collagen were significantly reduced from baseline (P<.001) for all active treatment groups at all time points; no changes were found for the placebo group. For women treated with CEEs alone, the gains in spine BMD for the group taking CEEs, 0.625 mg/d, were significantly higher than those of the group taking CEEs, 0.3 mg/d (P=.02), but not the group treated with CEEs, 0.45 mg/d (P=.48). Conclusions Doses of CEEs or CEEs-MPA lower than 0.625 mg/d effectively increase BMD and BMC in early postmenopausal women.
引用
收藏
页码:2668 / 2676
页数:9
相关论文
共 24 条
[1]   Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding [J].
Archer, DF ;
Dorin, M ;
Lewis, V ;
Schneider, DL ;
Pickar, JH .
FERTILITY AND STERILITY, 2001, 75 (06) :1080-1087
[2]   Effects of hormone therapy on bone mineral density - Results from the postmenopausal estrogen/progestin interventions (PEPI) trial [J].
Bush, TL ;
Wells, HB ;
James, MK ;
BarrettConnor, E ;
Marcus, R ;
Greendale, G ;
Hunsberger, S ;
McGowan, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (17) :1389-1396
[3]   Patient-identified needs for hormone replacement therapy counseling: A qualitative study [J].
Connelly, MT ;
Ferrari, N ;
Hagen, N ;
Inui, TS .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (04) :265-268
[4]   A CONTROLLED TRIAL OF THE EFFECT OF CALCIUM SUPPLEMENTATION ON BONE-DENSITY IN POSTMENOPAUSAL WOMEN [J].
DAWSONHUGHES, B ;
DALLAL, GE ;
KRALL, EA ;
SADOWSKI, L ;
SAHYOUN, N ;
TANNENBAUM, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (13) :878-883
[5]   Personal perspective on low-dosage estrogen therapy for postmenopausal women [J].
Ettinger, B .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 1999, 6 (03) :273-276
[6]  
GALLAGHER JC, 1991, AM J MED, V90, P171
[7]   Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women [J].
Gambacciani, M ;
Ciaponi, M ;
Cappagli, B ;
Genazzani, AR .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2001, 185 (05) :1180-1185
[8]   Low-dose esterified estrogen therapy - Effects on bone, plasma estradiol concentrations, endometrium, and lipid levels [J].
Genant, HK ;
Lucas, J ;
Weiss, S ;
Akin, M ;
Emkey, R ;
McNaneyFlint, H ;
Downs, R ;
Mortola, J ;
Watts, N ;
Yang, HM ;
Banav, N ;
Brennan, JJ ;
Nolan, JC .
ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (22) :2609-2615
[9]   QUANTITATIVE COMPUTED-TOMOGRAPHY OF VERTEBRAL SPONGIOSA - A SENSITIVE METHOD FOR DETECTING EARLY BONE LOSS AFTER OOPHORECTOMY [J].
GENANT, HK ;
CANN, CE ;
ETTINGER, B ;
GORDAN, GS .
ANNALS OF INTERNAL MEDICINE, 1982, 97 (05) :699-705
[10]   Medroxyprogesterone acetate enhances the spinal bone mineral density response to oestrogen in late post-menopausal women [J].
Grey, A ;
Cundy, T ;
Evans, M ;
Reid, I .
CLINICAL ENDOCRINOLOGY, 1996, 44 (03) :293-296